Last reviewed · How we verify

DTaP-Hep B-IPV Vaccine — Competitive Intelligence Brief

DTaP-Hep B-IPV Vaccine (DTaP-Hep B-IPV Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vaccine. Area: Immunology.

phase 3 Vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

DTaP-Hep B-IPV Vaccine (DTaP-Hep B-IPV Vaccine) — National Institute of Allergy and Infectious Diseases (NIAID). This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, hepatitis B, and polio viruses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DTaP-Hep B-IPV Vaccine TARGET DTaP-Hep B-IPV Vaccine National Institute of Allergy and Infectious Diseases (NIAID) phase 3 Vaccine
Comirnaty BNT162b2 (tozinameran) Pfizer Inc. marketed vaccine SARS-CoV-2 virus 2021-08-23
Prevnar 20 pneumococcal 20-valent conjugate vaccine (PCV20) Pfizer Inc. marketed Pneumococcal conjugate vaccine Streptococcus pneumoniae capsular polysaccharides (20 serotypes) 2021-06-08
IPV at 6 weeks of age IPV at 6 weeks of age Centers for Disease Control and Prevention marketed Inactivated viral vaccine Poliovirus types 1, 2, and 3
Varicella Virus Vaccine Live Varicella Virus Vaccine Live Sanofi Pasteur, a Sanofi Company marketed Live attenuated vaccine Varicella-zoster virus (VZV)
Streptococcus pneumoniae serotype 3 Streptococcus pneumoniae serotype 3 University of Oxford marketed Pneumococcal conjugate vaccine Streptococcus pneumoniae serotype 3 capsular polysaccharide
PCRA (Intermittent injection) PCRA (Intermittent injection) Örebro University, Sweden marketed Cancer vaccine / Autologous cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Vaccine class)

  1. GlaxoSmithKline · 16 drugs in this class
  2. Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
  3. Pfizer · 6 drugs in this class
  4. International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
  5. Henogen · 3 drugs in this class
  6. Pfizer Inc. · 2 drugs in this class
  7. Sanofi · 2 drugs in this class
  8. Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
  9. BioNTech · 2 drugs in this class
  10. Merck Sharp & Dohme LLC · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DTaP-Hep B-IPV Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/dtap-hep-b-ipv-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: